These data, in concert with the evidence described above that BRAF V600E overexpression increases proliferation and DNA instability of thyroid cells and the central role of BRAF as a critical signalling node in RET/PTC-induced thyroid cell proliferation, suggest BRAF as an appropriate therapeutic target for thyroid cancer. This evidence concerns the gene RET and thyroid cancer.